Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CD20 CD3 双特异性抗体 TCE 治疗自免 - 礼进生物
TCE platform with CD3 antibodies for solid tumors | NeoMab Bio posted ...
CD3 Proteins Empower Breakthroughs in TCE Development
Schematic representation of TCE and NKCE formats approved or in ...
We develop a TCE platform with anti-TCR/CD3 nanobodies, instead of ...
Development of a TCR-like CAR format (TCAR) that mediates antigen ...
Platform TCE model simulation of two-dimensional contour plots for the ...
First-in-Class Claudin18.2/CD3 TCE Enters Phase III Trials for ...
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in ...
| Common structures of TCE proteins. This figure illustrates common ...
Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive ...
TCR-CD3复合物 | 破局 CD3 抗体开发，驱动TCE双抗创新|TED|自身免疫性疾病|细胞|免疫|靶向_新浪新闻
CD3 Proteins – KACTUS
CD3 x BCMA BISPECIFICS
Select the Best Format for Your T Cell Engager – Viviabiotech
Illustration of bi-specific TCE (BiTE) and tri-specific TCE (TriTE ...
Precision-Engineered CD3 T-Cell Engagers for Solid Tumours: Conditional ...
Effect of CD3 binding affinity Kd (CD3-TCE) on biTTC and moTTC density ...
Masking of CD3 binder reversibly impairs binding to CD3ε antigen ...
2: The TCR structure, comparison and the CD3 complex: In this picture ...
Fine-tuned CD3 Affinity: Desired Balance between Antitumor Activity and ...
双特异性T细胞衔接器（TCE）-CD3双抗-TCE作用机制/技术平台-德泰生物
CD3亲和力微调：抗肿瘤活性与安全性之间的理想平衡-TCE研发-德泰生物
slide8
CD3双抗设计考量因素及国内项目梳理 - 知乎
小禾说 | 自身免疫疾病靶点与模型系列(16)——CD3-TCE爆火，自免双抗/多抗疗法进入新阶段 - 知乎
【AACR 2025】上细前沿突破四 | TCE核心平台：基于抗CD3与肿瘤特异性靶点的纳米抗体库为精准免疫治疗提供核心工具
Molecular Construction of T Cell Engagers: Formats Matter
T细胞衔接器双抗(TCE)的作用机制及其药物在肿瘤治疗中的应用_生物器材网
Structural design and biochemical properties of bispecific T-cell ...
T-Cell Engagers—The Structure and Functional Principle and Application ...
CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond ...
CD3/CD19/BCMA 从肿瘤免疫到自身免疫性疾病的多面利器 - 知乎
1068 ATG-107, a novel 2+1 CD3-based T cell engager (TCE) targeting FLT3 ...
(PDF) Perspective: Designing T-Cell Engagers With Better Therapeutic ...
从Linvoseltamab最新临床数据公布，看BCMA/CD3双抗研究进展 - 知乎
【AACR 2025】上细前沿突破四 | TCE核心平台：基于抗CD3与肿瘤特异性靶点的纳米抗体库为精准免疫治疗提供核心工具医药新闻 ...
Frontiers | Trispecific eFab-eIg T-cell engagers targeting HER2 and HER3
Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune ...
Frontiers | Current landscape and future directions of bispecific ...
1067 ATG-201, a novel ‘2+1’ CD19-targeted T-cell engager (TCE) for the ...
【双抗大有可为】2022双抗大飞跃-公司新闻-北京百普赛斯生物科技股份有限公司
Trispecific antibodies for cancer immunotherapy - Yao - 2023 ...
B7-H6/CD3 T-cell Engager Results | InOncology – Boehringer Ingelheim
Anti-human CD3-CD28 | For T cell expansion and Activation | InvivoGen
BCMA/CD3丨从FDA第五款双抗看全球进展 2022年10月25日，FDA加速批准 强生 BCMA/CD3双抗TECVAYLI ...
文献分享：一种新型T细胞衔接器双特异性抗体
DLL3 – A Breakthrough Target for Small Cell Lung Cancer Therapy-DIMA ...
克服癌症中CD3+ T细胞重定向相关的挑战（二）：TCE与激动剂联用策略[1]
An optimal antitumor response by a novel CEA/CD3 bispecific antibody ...
TCE三抗///CD3/CD2/ULBP2/5/6三抗///鳞状肿瘤临床前疗效 - 知乎
T-cell engager CD3ε | Highlighted Client Publication | genOway
CD3蛋白：TCE药物开发的核心引擎 - 知乎
Human Cord Blood CD3+ T Cells, Pure and Viable | HumanCellsBio.com ...
In vivo efficacy of LY6G6D/CD3 TcE. (A-C) Anti-tumor activity of ...
Engineering a tumor selective prodrug T-cell engager bispecific ...
(PDF) 1384 LNK101, a highly differentiated T-cell engager (TCE ...
安进/百济 CD3/STEAP1 双抗国内申报临床_试验_细胞_平台
Innovations in cancer immunotherapy: Bi-specific T cell engagers | CAS
Schematic representation of the relationship between dose, exposure and ...
靶点荟萃 | CD3：TCE双抗/多抗的黄金靶点-技术前沿-资讯-生物在线
CD3蛋白助力突破TCE開發瓶頸
恺佧生物科技（上海）有限公司
2023AACR丨再生元公布BCMA/CD3双抗数据及计划 再生元 目前有两款BCMA/CD3双抗，REGN5459和REGN5458。今年的 ...
一个不受sMSLN影响能够选择性杀伤高表达MSLN靶细胞的TCE(T cell engager) - 平头哥
突破：首个实体瘤TCE双抗获批上市 今日，Amgen宣布，FDA加速批准其靶向DLL3/CD3的双特异抗体tarlatamab上市，用于治疗 ...
Therapeutic potential of CD20/CD3 bispecific antibodies in the ...
BigPharm|葛兰素史克——15亿美元：药明生物与GSK就多款创新TCE双抗/多抗达成许可协议 - 知乎
CD3蛋白助力突破TCE开发瓶颈|肿瘤_新浪财经_新浪网
T cell-engager：产生应答的T cells表型详解_生物器材网
Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
CD3E | Expert tips & troubleshooting | Abcam
1191 ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting ...
LY6G6D is a tumor antigen specifically expressed in CRC. (A-C) LY6G6D ...
Excellent Human-Monkey Cross-Reactivity ! This CD3-VHH Potently ...
Selected signalling proteins recruited to the T‐cell receptor–CD3 ...
B7-H6/CD3 T-cell engager | InOncology – Boehringer Ingelheim
TCE赛道火爆！新型CD3纳米抗体来了，引领下一代TCE研发突破医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Frontiers | Design of a Trispecific Checkpoint Inhibitor and Natural ...
Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC ...
抗CD3/抗CD28双特异性抗原结合分子的制作方法
T cell-engager：哪些“T cells”在产生应答|cells|TCE|CD8|CD3|细胞|肿瘤|-健康界
T细胞靶向的双特异性抗体(TCE)引起CRS的机制探究 - 平头哥
Frontiers | T-cell virtuosity in ‘‘knowing thyself”
